30 Day Trial

ORTHOKNOW content is posted to these pages in real time.

Monthly compilations are available in PDF form.

1Q14 Revenue: Tornier

$89.0MM, +7% (U.S. $49.9MM, +4%; ex-U.S. $39.0MM, +10%)

  • Total Extremities $72.0MM, +7% (Upper $53.1MM, +10%, Lower $15.0MM, +0.1%, Sports Med/Biologics $3.8MM, -6%)
  • Large Joints/Other $17.0MM, +7%


  • Aequalis Ascend shoulder products continue to gain global surgeon acceptance
  • Gradually expanding rollout of Ascend Flex threaded post baseplate over 2014
  • Expecting to complete 2-year follow-up on patients in study of Simpliciti stemless shoulder, file for 510(k) clearance in early 2015
  • Performed 1st commercial total shoulder reverse arthroplasty procedure in Japan, using Aequalis Reverse
  • Salto Talaris ankle sales offset by lower foot/ankle fixation sales, which were impacted by U.S. sales transition
  • Sports Med growth affected by decline in soft tissue anchors
  • Launched new minimally invasive hip instrumentation in Europe
  • Goal is 85% of U.S. sales reps dedicated to either upper or lower extremities by year-end
  • Modest price pressure (~1%) in extremities
  • Double-digit growth in ex-U.S. lower extremities, supported by OrthoHelix products